HIV-infected former plasma donors in rural central China: From infection to survival outcomes, 1985-2008

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Dou, Zhihui ^a   Chen, Ray Y ^b   Wang, Zhe ^c   Ji, Guoping ^d   Peng, Guoping ^e   Qiao, Xiaochun ^f   Fu, Jihua ^g   Meng, Xiangdong ^h   Bulterys, Marc ⁱ   Ma, Ye ^a   Zhao, Yan ^a   Wang, Ning ^a   Zhang, Fujie ^a,j  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Anhui Center for Disease Control and Prevention   (China)

^e Hubei Center for Disease Control and Prevention   (China)

^f Shanxi Provincial Center for Disease Control and Prevention   (China)

^g SHANDONG CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^h Jilin Center for Disease Control and Prevention   (China)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j CAPITAL MEDICAL UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD DONOR; CHINA; CONTROLLED STUDY; DEATH; EPIDEMIC; FEMALE; GEOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; SURVIVAL RATE; TREATMENT OUTCOME; ADOLESCENT; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RURAL POPULATION; SURVIVAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BLOOD DONORS; CHINA; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RURAL POPULATION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 78149434616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013737     Document Type: Article

References (34)

1. Zhang FJ, Chen RY, Lo SN, Ma Y (2008) Country Review: China. In: Zuniga JM, Whiteside A, Ghaziani A, Bartlett JG, eds. A Decade of HAART. Oxford: Oxford University Press.
2. He N, Detels R (2005) The HIV epidemic in China: history, response, and challenge. Cell Res 15: 825-832.
3. Ministry of Health. Provisions for the Monitoring and Control of AIDS. Beijing: December 26, 1987.
4. Wu Z, Liu Z, Detels R (1995) HIV-1 infection in commercial plasma donors in China. Lancet 346: 61-62.
5. Qian HZ, Vermund SH, Kaslow RA, Coffey CS, Chamot E, et al. (2006) Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China. AIDS 20: 1429-1435.
6. Qian HZ, Yang Z, Shi X, Gao J, Xu C, et al. (2005) Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China Integrated Programs for Research on AIDS. J Infect Dis 192: 1694-1700.
7. Ji G, Detels R, Wu Z, Yin Y (2006) Correlates of HIV infection among former blood/plasma donors in rural China. AIDS 20: 585-591.
8. Wu Z, Rou K, Detels R (2001) Prevalence of HIV infection among former commercial plasma donors in rural eastern China. Health Policy Plan 16: 41-46.
9. (December 30, 1996) Blood Products Regulation Act. Central Government of the People's Republic of China.
10. Wu Z, Sun X, Sullivan SG, Detels R (2006) Public health. HIV testing in China. Science 312: 1475-1476.
11. Sun X, Wang N, Li D, Zheng X, Qu S, et al. (2007) The development of HIV/ AIDS surveillance in China. AIDS 21 Suppl 8: S33-38.
12. Zhang F, Haberer JE, Wang Y, Zhao Y, Ma Y, et al. (2007) The Chinese free antiretroviral treatment program: challenges and responses. AIDS 21 Suppl 8: S143-148.
13. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R (2007) Evolution of China's response to HIV/AIDS. Lancet 369: 679-690.
14. Zhang F, Dou Z, Yu L, Xu J, Jiao JH, et al. (2008) The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 47: 825-833.
15. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, et al. (2009) Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 151: 241-251,W-252.
16. Zhang XF, Liu XZ, Tao XR, Huang T, Su SL, et al. (2005) [The epidemiological study on human immunodeficiency virus infection among paid blood donors living in Shandong provincial China Comprehensive Response Project Areas]. Zhonghua Liu Xing Bing Xue Za Zhi 26: 314-316.
17. Zheng X, Wang Z, Xu J, Huang S, Wang C, et al. (2000) [The epidemiological study of HIV infection among paid blood donors in one county of China]. Zhonghua Liu Xing Bing Xue Za Zhi 21: 253-255.
18. Xu JQ, Wang JJ, Han LF, Xu C, Ruan YH, et al. (2006) Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. Chin Med J (Engl) 119: 1941-1948.
19. Ma Y, Zhang F, Zhao Y, Zang C, Zhao D, et al. (2009) Cohort Profile: The Chinese national free antiretroviral treatment cohort. Int J Epidemiol.
20. (January 2005) China Free ART Manual. Beijing: Chinese Center for Disease Control and Prevention.
21. Wang N (1991) [First reported case of AIDS in China]. Zhonghua Yi Xue Za Zhi 71: 671-673, 646.
22. Ghys PD, Zaba B, Prins M (2007) Survival and mortality of people infected with HIV in low and middle income countries: results from the extended ALPHA network. AIDS 21 Suppl 6: S1-S4.
23. Volkow P, Lopez-Vidal Y, Amieba RI, Hernandez M (2001) Paid plasma donation and risk of blood-borne diseases in blood-product recipients. Lancet 358: 2001-2002.
24. Zhang L, Chen Z, Cao Y, Yu J, Li G, et al. (2004) Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol 78: 13591-13599.
25. Wang S (1991) [An epidemiological study on hepatitis C among the plasmapheretic donors in two villages with a 5-year history of plasma donation]. Zhonghua Yi Xue Za Zhi 71: 76-78.
26. Sun YD, Meng ZD, Wang SY, Chen XR, Sun DG, et al. (1991) Epidemiologic investigation on an outbreak of hepatitis C. Chin Med J (Engl) 104: 975-979.
27. Brettle RP, McNeil AJ, Burns S, Gore SM, Bird AG, et al. (1996) Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985. AIDS 10: 419-430.
28. Glynn JR, Sonnenberg P, Nelson G, Bester A, Shearer S, et al. (2007) Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up. AIDS 21: 625-632.
29. Porter K, Zaba B (2004) The empirical evidence for the impact of HIV on adult mortality in the developing world: data from serological studies. AIDS 18 Suppl 2: S9-S17.
30. Pantaleo G, Graziosi C, Fauci AS (1993) New concepts in the immunopatho-genesis of human immunodeficiency virus infection. N Engl J Med 328: 327-335.
31. Pantaleo G, Graziosi C, Fauci AS (2008) Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 84 Suppl 1: i31-i36.
32. Pantaleo G, Graziosi C, Fauci AS (2000) Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 355: 1131-1137.
33. Todd J, Glynn JR, Marston M, Lutalo T, Biraro S, et al. (2007) Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS 21 Suppl 6: S55-63.
34. Ward JW, Bush TJ, Perkins HA, Lieb LE, Allen JR, et al. (1989) The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. N Engl J Med 321: 947-952.